「Leishmaniasis」の版間の差分

提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
ナビゲーションに移動 検索に移動
16行目: 16行目:
 
*promastigote - 10-25 μm
 
*promastigote - 10-25 μm
 
**with flagellum
 
**with flagellum
 +
**transform from amastigote inside sandfly midgut
 +
**proliferate inside midgut
 +
**introduced into human skin directly from sandfly midgut during sandfly bite
 
**phagocytized by macrophage
 
**phagocytized by macrophage
 
*amastigote - 2-4 μm
 
*amastigote - 2-4 μm
23行目: 26行目:
 
*vector: sandfly
 
*vector: sandfly
 
*host: human, dog, rodent
 
*host: human, dog, rodent
 +
 +
===sand flly===
 +
*''Phlebotomus'' spp.
 +
**Eurasian
 +
*''Lutzomya'' spp.
 +
**Latin America
 +
*Feed during night
 +
 +
  
 
==clinical manifestation==
 
==clinical manifestation==
42行目: 54行目:
 
**Mediterranean, China, South America
 
**Mediterranean, China, South America
 
**dog is reservoir
 
**dog is reservoir
 +
 +
====diagnosis of visceral leishmania====
 +
*smear of bone marrow aspiration, lymph node or spleen aspiration
 +
**sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
 +
*culture in NNN media
 +
*immunochromatographical detection of rk39 antigen
 +
**dip stick form
  
 
====post kala-azar dermal leishmanisis (PKDL)====
 
====post kala-azar dermal leishmanisis (PKDL)====
63行目: 82行目:
  
 
*cutaneous leishmaniasis by ''L. donovani'' is reported in Sri Lanka
 
*cutaneous leishmaniasis by ''L. donovani'' is reported in Sri Lanka
 +
 +
====diagnosis of cutaneous leishmaniasis====
 +
*smear of fine needle aspirate or biopsy of skin lesion
 +
*serological test is of no use; low sensitivity and variable specificity
  
 
===mucocutaneous leishmania===
 
===mucocutaneous leishmania===
71行目: 94行目:
 
*progressive ever without treatment
 
*progressive ever without treatment
 
*secondary bacterial infection
 
*secondary bacterial infection
 +
 +
====diagnosis of mucocutaneous leishmaniasis====
 +
*leishmania is scarce in mucosal lesion
 +
**strong local immune response
 +
*serology or molecular
  
 
==emerging novel leishmaniasis==
 
==emerging novel leishmaniasis==
 
*in Thailand
 
*in Thailand
 
*''L. siamensis'', ''L. martiniquensis''
 
*''L. siamensis'', ''L. martiniquensis''

2021年4月22日 (木) 17:56時点における版

taxonomy

  • phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
    • Plasmodium belongs to phylum Apicomplexa

morphology

  • single flagellum
  • kinetoplast - aggregation of DNA
  • similar to Trypanosoma

epidemiology

  • 700,000 - 1 mil. new cases per year

20,000-30,000 deaths per year

life cycle

  • parasitize in human macrophage
  • promastigote - 10-25 μm
    • with flagellum
    • transform from amastigote inside sandfly midgut
    • proliferate inside midgut
    • introduced into human skin directly from sandfly midgut during sandfly bite
    • phagocytized by macrophage
  • amastigote - 2-4 μm
    • transform from promastigote and propagate inside macrophage
    • transform to promastigote inside sandfly midgut
  • simpler than Trypanosoma
  • vector: sandfly
  • host: human, dog, rodent

sand flly

  • Phlebotomus spp.
    • Eurasian
  • Lutzomya spp.
    • Latin America
  • Feed during night


clinical manifestation

visceral leishmania

  • most serious
  • same as Kala-azar
    • Latin "black fever"
  • fever
  • weight loss
  • hepatosplenomegaly
  • anemia
  • 50,000-90,000 new cases per year
    • mainly children affected
    • India, Ethiopia, South Sudan, Brazil
  • L. donovani
    • India, Africa
    • anthroponotic = maintained in human-to-human infection
  • L. infantum (formerly L. chagasi was thought separated species)
    • Mediterranean, China, South America
    • dog is reservoir

diagnosis of visceral leishmania

  • smear of bone marrow aspiration, lymph node or spleen aspiration
    • sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
  • culture in NNN media
  • immunochromatographical detection of rk39 antigen
    • dip stick form

post kala-azar dermal leishmanisis (PKDL)

  • skin manifestation after completion of Tx of visceral leishmaniasis
    • macular type, papular type, nodular type
  • Leishmania may be detected from skin specimen in some cases
    • possible reservoir


cutaneous leishmania

  • most common
  • same as Oriental sore, Chiclero ulcer (in Latin America)
  • papule, nodule → ulcer → scar
  • basically self-limited
  • rarely diffuce or disseminated
  • 600,000-1 mil. new cases per year
  • Afghanistan, Algeria, Brazil, Colombia, Iran, Syria
    • imported in Texas, US in 2015
  • L. tropica, L. mexicana, L. amazonensis and other species >20
  • Rhombomys opimus (great gerbil) is primary reservoir
  • cutaneous leishmaniasis by L. donovani is reported in Sri Lanka

diagnosis of cutaneous leishmaniasis

  • smear of fine needle aspirate or biopsy of skin lesion
  • serological test is of no use; low sensitivity and variable specificity

mucocutaneous leishmania

  • same as Espundia, white leprosy
  • lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
  • L. braziliensis, L. panamensis
  • Bolivia, Brazil, Peru
  • progressive ever without treatment
  • secondary bacterial infection

diagnosis of mucocutaneous leishmaniasis

  • leishmania is scarce in mucosal lesion
    • strong local immune response
  • serology or molecular

emerging novel leishmaniasis

  • in Thailand
  • L. siamensis, L. martiniquensis